title: Syngeneic marrow transplantation in multiple myeloma.
abstract: Two cases of IgA multiple myeloma treated with syngeneic bone marrow transplant and a non-total body irradiation (TBI) conditioning regimen are reported. Both patients presented with stage III disease which responded to standard chemotherapeutic management. The myelo-ablative program for transplant consisted of busulfan and cyclophosphamide (Bu/Cy). Evaluation at 40 days post-transplant revealed no evidence of residual myeloma in either patient. One patient died of disseminated Aspergillus fumigatus at day 73 post-transplant. The other patient relapsed at 18 months post-transplant. This conditioning regimen shows efficacy in aggressive myeloma and could be considered earlier in the disease.
authors.affiliation: Hahnemann University Hospital, Philadelphia, PA 19102-1192.
authors.forename: D
authors.initials: D
authors.lastname: Topolsky
authors.forename: P
authors.initials: P
authors.lastname: Crilley
authors.forename: N
authors.initials: N
authors.lastname: Leasure
authors.forename: S
authors.initials: S
authors.lastname: Bulova
authors.forename: I
authors.initials: I
authors.lastname: Brodsky
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D014185:Transplantation, Isogeneic; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide; D002066:Busulfan